Jacobs Levy Equity Management Inc. Acquires Shares of 42,323 Twist Bioscience Corporation $TWST

Jacobs Levy Equity Management Inc. acquired a new stake in shares of Twist Bioscience Corporation (NASDAQ:TWST) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 42,323 shares of the company’s stock, valued at approximately $1,662,000. Jacobs Levy Equity Management Inc. owned approximately 0.07% of Twist Bioscience as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. ARK Investment Management LLC boosted its holdings in shares of Twist Bioscience by 11.5% during the 1st quarter. ARK Investment Management LLC now owns 6,241,595 shares of the company’s stock valued at $245,045,000 after acquiring an additional 645,730 shares during the last quarter. Vanguard Group Inc. lifted its position in Twist Bioscience by 1.0% during the first quarter. Vanguard Group Inc. now owns 5,867,459 shares of the company’s stock valued at $230,356,000 after purchasing an additional 60,276 shares during the period. EdgePoint Investment Group Inc. bought a new position in Twist Bioscience during the first quarter valued at approximately $43,705,000. Nuveen LLC bought a new position in Twist Bioscience during the first quarter valued at approximately $31,960,000. Finally, American Century Companies Inc. lifted its position in Twist Bioscience by 0.9% during the first quarter. American Century Companies Inc. now owns 763,406 shares of the company’s stock valued at $29,971,000 after purchasing an additional 7,054 shares during the period.

Insider Activity at Twist Bioscience

In other Twist Bioscience news, CEO Emily M. Leproust sold 2,265 shares of Twist Bioscience stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $25.76, for a total transaction of $58,346.40. Following the transaction, the chief executive officer owned 634,740 shares of the company’s stock, valued at $16,350,902.40. The trade was a 0.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Adam Laponis sold 2,449 shares of Twist Bioscience stock in a transaction that occurred on Wednesday, July 9th. The shares were sold at an average price of $38.15, for a total transaction of $93,429.35. Following the transaction, the chief financial officer directly owned 103,569 shares in the company, valued at $3,951,157.35. This represents a 2.31% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 8,911 shares of company stock worth $288,159 in the last ninety days. Insiders own 3.01% of the company’s stock.

Twist Bioscience Stock Performance

TWST opened at $24.16 on Thursday. The company has a current ratio of 3.90, a quick ratio of 3.60 and a debt-to-equity ratio of 0.03. The company has a market cap of $1.46 billion, a price-to-earnings ratio of -16.66 and a beta of 2.31. The company’s 50 day moving average is $31.02 and its 200 day moving average is $34.47. Twist Bioscience Corporation has a 12-month low of $24.07 and a 12-month high of $55.33.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings results on Monday, August 4th. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.07. Twist Bioscience had a negative net margin of 23.51% and a negative return on equity of 29.03%. The business had revenue of $96.06 million for the quarter, compared to the consensus estimate of $95.52 million. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, equities research analysts predict that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on TWST shares. Evercore ISI set a $46.00 price objective on shares of Twist Bioscience in a research report on Monday, August 4th. Cowen restated a “buy” rating on shares of Twist Bioscience in a research report on Monday, August 4th. Nine equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Twist Bioscience currently has an average rating of “Moderate Buy” and a consensus price target of $49.40.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.